Abstract
Cancer is one of the most causes of disease-related mortality. One of the major causes of this has been the delay in diagnosis and considerable failure of therapeutic options for cancer. The failure is mainly due to frequent metastasis and a high degree of resistance. The simplest solution to the problem lies in either early diagnosis, efficacious therapy, or continuous monitoring. The identification of sensitive and reliable biomarkers for early screening and therapeutic monitoring has been a thrust area of research. The available alternative, despite the efforts, carries several limitations including high toxicity associated with current therapeutic agents and a high degree of genetic variability among cancer types. Thus, there is an unmet need for the development of safer therapeutic alternatives and better diagnostic methods. The field of theranostics has provided an important ray of hope for the advancement of breast cancer therapeutics. Theranostics deal with the targeting receptor for both therapeutic as well as diagnostic purposes. The field of theranostics has been efficiently complemented by the fields of nanomedicine and nuclear medicine. Various aptamers, antibodies, enzymes, and proteins have been conjugated and functionalized to form theranostic nanoparticles and radiopharmaceuticals with the patient-centric approach. The current chapter discusses the concepts and applications of theranostic approaches for the diagnosis and treatment of cancer with a focus on the recent advancement in the field.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020. CA Can J Clin 70, 7–30 (2020)
M.Z. Ahmad, S. Akhter, G.K. Jain et al., Metallic nanoparticles: technology overview & drug delivery applications in oncology. Exp. Op. Drug. Del. 7, 927–942 (2010)
M.Z. Ahmad, S. Akhter, N. Mallik et al., Application of decoy oligonucleotides as novel therapeutic strategy: a contemporary overview. Curr. Drug. Discov. Tech. 10, 71–84 (2013)
M.Z. Ahmad, M. Rizwanullah, J. Ahmad, et al., Progress in nanomedicine-based drug delivery in designing of chitosan nanoparticles for cancer therapy. Int. J. Poly. Mat. Poly. Biomat. 1–22 (2021)
Global cancer observatory (2020). Available from: https://gco.iarc.fr/
GLOBOCAN 2020: New Global Cancer Data (2020). Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data
S. Tran, P.J. De Giovanni, B. Piel et al., Cancer nanomedicine: a review of recent success in drug delivery. Clin. Trans. Med. 6, 44 (2017)
N. Ahmed, H. Fessi, A. Elaissari, Theranostic applications of nanoparticles in cancer. Drug Discov. Tod. 17, 928–934 (2012)
Z. Zhang, J. Wang, C. Chen, Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging. Adv. Mat. 25, 3869–3880 (2013)
M.Z. Ahmad, S. Akhter, Z. Rahman et al., Nanometric gold in cancer nanotechnology: current status and future prospect. J. Phar. Pharmacol. 65, 634–651 (2013)
M. Rahman, M.Z. Ahmad, I. Kazmi et al., Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr. Drug Discov. Tech. 9, 319–329 (2012)
S. Akhter, M.Z. Ahmad, F.J. Ahmad et al., Gold nanoparticles in theranostic oncology: current state-of-the-art. Exp. Op. Drug Deliv. 9, 1225–1243 (2012)
M.Z. Ahmad, J. Ahmad, A. Haque et al., Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Exp. Rev. Vacc. 19, 1053–1071 (2020)
X.X. Peng, A.K. Tiwari, H.C. Wu et al., Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin. J. Can. 31, 110–118 (2012)
M. Wang, J. Zhao, L. Zhang et al., Role of tumor microenvironment in tumorigenesis. J. Can. 8, 761–773 (2017)
V. Negri, J. Pacheco-Torres, D. Calle et al., Carbon nanotubes in biomedicine. Top Curr. Chem. 378, 15 (2020)
Y.Y. Tan, P.K. Yap, G.L. Xin Lim et al., Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics. Chem. Biol. Int. 329, 109221 (2020)
J. Shi, P.W. Kantoff, R. Wooster et al., Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Can. 17, 20–37 (2016)
B. Zhang, Y. Wang, G. Zhai, Biomedical applications of the graphene-based materials. Mat. Sci. Eng. C 61, 953–964 (2016)
Y.G. Assaraf, A. Brozovic, A.C. Goncalves et al., The multi-factorial nature of clinical multidrug resistance in cancer. Drug Res. Up 46, 100645 (2019)
Q. Cui, J.Q. Wang, Y.G. Assaraf et al., Modulating ROS to overcome multidrug resistance in cancer. Drug Res. Up 41, 1–25 (2018)
Y.J. Li, Y.H. Lei, N. Yao et al., Autophagy and multidrug resistance in cancer. Chin. J. Can. 36, 52 (2017)
S.Y. Chun, Y.S. Kwon, K.S. Nam et al., Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumor spheres by inhibiting the drug efflux function of ABC transporters. Biomed. Pharmacother. 72, 37–43 (2015)
G. Filomeni, P. Turella, M.L. Dupuis et al., 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol. Can. Thera. 7, 371–379 (2008)
A. Bedi, J.P. Barber, G.C. Bedi et al., BCRABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86, 1148–1158 (1995)
C.S. Wilson, L.J. Medeiros, R. Lai et al., DNA topoisomerase IIα in multiple myeloma: a marker of cell proliferation and not drug resistance. Mod. Path 14, 886–891 (2001)
H. Li, B.B. Yang, Friend or foe: the role of microRNA in chemotherapy resistance. Act Pharmacol Sin 34, 870–879 (2013)
L. Milane, Z. Duan, M. Amiji, Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Can. Cel. Int. 11, 3 (2011)
D.R. Camidge, W. Pao, L.V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Onc. 11, 473–481 (2014)
G.N. Zhang, C.R. Ashby, Y.K. Zhang et al., The reversal of antineoplastic drug resistance in cancer cells by β-elemene. Chin. J. Can. 34, 488–495 (2015)
P. Kumar, D.M. Zhang, K. Degenhardt et al., Autophagy and transporter-based multi-drug resistance. Cell 1, 558–575 (2012)
R.J. Kathawala, Y.J. Wang, C.R. Ashby Jr. et al., Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin. J. Can. 33, 223–230 (2014)
N. Anreddy, P. Gupta, R. Kathawala et al., Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. Molecules 19, 13848–13877 (2014)
S.K. Konig, M. Herzog, D. Theile et al., Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J. Antimic Chemother. 65, 2319–2328 (2010)
Z. Li, S. Tan, S. Li, Q. Shen et al., Cancer drug delivery in the nano era: an overview and perspectives. Oncol. Rep. 38, 611–624 (2017)
U.H. Gala, D.A. Miller, R.O. Williams, Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim. Biophy. Act Rev. Can. 1873, 188319 (2019)
E.D. Agdeppa, M.E. Spilker, A review of imaging agent development. AAPS J. 11, 286–299 (2009)
D.S. Shewach, R.D. Kuchta, Introduction to cancer chemotherapeutics. Chem. Rev. 109, 2859–2861 (2009)
S. Gurunathan, M.H. Kang, M. Qasim et al., Nanoparticle-mediated combination therapy: two-in-one approach for cancer. Int. J. Mol. Sci. 19, 3264 (2018)
R.C. Maranhao, C.G. Vital, T.M. Tavoni et al., Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents. Exp. Op. Drug Deliv. 14, 1217–1226 (2017)
A. Ruhle, P.E. Huber, R. Saffrich et al., The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. Int. J. Can. 143, 2628–2639 (2018)
N.M. Kuderer, D.C. Dale, J. Crawford et al., Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106, 2258–2266 (2006)
M. Volkova, R. Russell, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 7, 214–220 (2012)
R.G. Selker, S.A. Jacobs, P.B. Moore et al., 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis. Neurosurgery 7, 560–565 (1980)
A.L. Kunkler, E.M. Binkley, D. Mantopoulos et al., Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefe’s Arc Clin. Exp. Ophth. 257, 1771–1781 (2019)
N. Saraswat, A. Sood, R. Verma et al., Nail changes induced by chemotherapeutic agents. Ind. J. Dermatol. 65, 193–198 (2020)
F. Farjadian, A. Ghasemi, O. Gohari et al., Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine 14, 93–126 (2018)
J.H. Park, S. Lee, J.H. Kim et al., Polymeric nanomedicine for cancer therapy. Prog. Poly Sci. 33, 113–137 (2008)
J.I. Hare, T. Lammers, M.B. Ashford et al., Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv. Drug Deliv. Rev. 108, 25–38 (2017)
S.M. Moghimi, A.C. Hunter et al., Nanomedicine: current status and future prospects. FASEB J. 19, 311–330 (2005)
J. Zhu, M. Xu, M. Gao et al., Graphene oxide induced perturbation to plasma membrane and cytoskeletal meshwork sensitize cancer cells to chemotherapeutic agents. ACS Nano 11, 2637–2651 (2017)
Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Can. Res. 46, 6387–6392 (1986)
E. Panzarini, L. Dini, Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy? Mol. Pharmaceut. 11, 2527–2538 (2014)
M. Brandl, Liposomes as drug carriers: a technological approach. Biotech. Ann. Rev. 7, 59–85 (2001)
A.E.H. De Mendoza, M.A. Campanero, F. Mollinedo et al., Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotech. 5, 323–343 (2009)
Y. Matsumura, T. Hamaguchi, T. Ura et al., Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Brit. J. Can. 91, 1775–1781 (2004)
J.H. Lee, S.W. Jung, I.S. Kim et al., Polymeric nanoparticle composed of fatty acids and poly(ethylene glycol) as a drug carrier. Int. J. Pharmaceut. 251, 23–32 (2003)
Z. Liu, Y. Jiao, Y. Wang et al., Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev. 60, 1650–1662 (2008)
S. Dakhil, W. Ensminger, K. Cho et al., Improved regional selectivity of hepatic arterial bcnu with degradable microspheres. Cancer 50, 631–635 (1982)
N. Nelken, P.A. Schneider, Advances in stent technology and drug-eluting stents. Sur. Clin. North Am. 84, 1203–1236 (2004)
J. Kreuter, Nanoparticles and microparticles for drug and vaccine delivery. J. Ana. 189, 503–505 (1996)
D. Breimer, Future challenges for drug delivery research. Adv. Drug Deliv. Rev. 33, 265–268 (1998)
A. Fernandez-Fernandez, R. Manchanda, A.J. McGoron, Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. App. Biochem. Biotech. 165, 1628–1651 (2011)
H. Sajja, M. East, H. Mao, Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr. Drug Discov. Tech. 6, 43–51 (2009)
P.S. Zangabad, S. Mirkiani, S. Shahsavari et al., Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications. Nanotech. Rev. 7, 95–122 (2018)
W.L. Tang, W.H. Tang, S.D. Li, Cancer theranostic applications of lipid-based nanoparticles. Drug Discov. Today 23, 1159–1166 (2018)
S. Bayda, M. Hadla, G. Corona et al., Inorganic nanoparticles for cancer therapy: a transition from lab to clinic. Curr. Med. Chem. 25, 4269–4303 (2018)
C.C. Lee, E.R. Gillies, M.E. Fox et al., A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Nat. Acad. Sci. 103, 16649–16654 (2006)
J.Y. Lee, D.Y. Choi, M.Y. Cho et al., Targeted theranostic nanoparticles: receptor-mediated entry into cells, pH-induced signal generation and cytosolic delivery. Small 10, 901–906 (2013)
X. Liu, B. Chen, X. Li et al., Self-assembly of BODIPY based pH-sensitive near-infrared polymeric micelles for drug-controlled delivery and fluorescence imaging applications. Nanoscale 7, 16399–16416 (2015)
M. Liong, J. Lu, M. Kovochich et al., Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2, 889–896 (2008)
E. Phillips, O. Penate-Medina, P.B. Zanzonico, et al., Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6, 260ra149–260ra149 (2014)
P. Singh, S. Pandit, V.R.S.S. Mokkapati et al., Gold nanoparticles in diagnostics and therapeutics for human cancer. Int. J. Mol. Sci. 19, 1979 (2018)
C.G. Hadjipanayis, R. Machaidze, M. Kaluzova et al., EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Can. Res. 70, 6303–6312 (2010)
C. Ansari, G.A. Tikhomirov, S.H. Hong et al., Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10, 566–575 (2013)
G. Von Maltzahn, J.H. Park, A. Agrawal et al., Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Can. Res. 69, 3892–3900 (2009)
C. Matea, T. Mocan, F. Tabaran et al., Quantum dots in imaging, drug delivery and sensor applications. Int. J. Nanomed. 12, 5421–5431 (2017)
M.E. Davis, J.E. Zuckerman, C.H.J. Choi et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070 (2010)
S.K. Libutti, G.F. Paciotti, A.A. Byrnes et al., Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Can. Res. 16, 6139–6149 (2010)
D. Ling, W. Park, S. Park et al., Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J. Am. Chem. Soc. 136, 5647–5655 (2014)
M. Kester, Y. Heakal, T. Fox et al., Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nan. Lett. 8, 4116–4121 (2008)
K. Yang, S. Zhang, G. Zhang et al., Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano. Lett. 10, 3318–3323 (2010)
J.K. Kim, K.J. Choi, M. Lee et al., Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33, 207–217 (2012)
D.G. You, V.G. Deepagan, W. Um et al., ROS-generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer. Sci. Rep. 6, 23200 (2016)
S. Lee, H. Koo, J.H. Na et al., Chemical tumor-targeting of nanoparticles based on metabolic glycoengineering and click chemistry. ACS Nano 8, 2048–2063 (2014)
B. Kang, M.B. Zheng, P. Song et al., Subcellular-scale drug transport via ultrasound-degradable mesoporous nanosilicon to bypass cancer drug resistance. Small 13, 1604228 (2017)
R. Duncan, The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347–360 (2003)
D.K. Mishra, R. Shandilya, P.K. Mishra, Lipid based nanocarriers: a translational perspective. Nanomed. Nanotech. Biol. Med. 14, 2023–2050 (2018)
A. El-Aneed, An overview of current delivery systems in cancer gene therapy. J. Contr. Rel. 94, 1–14 (2004)
L. Bromberg, Polymeric micelles in oral chemotherapy. J. Contr. Rel. 128, 99–112 (2008)
V.P. Torchilin, Structure and design of polymeric surfactant-based drug delivery systems. J. Contr. Rel. 73, 137–172 (2001)
M.L. Adams, A. Lavasanifar, G.S. Kwon, Amphiphilic block copolymers for drug delivery. J. Pharmaceut. Sci. 92, 1343–1355 (2003)
T. Merdan, J. Kopecek, T. Kissel, Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54, 715–758 (2002)
D.J. Glover, H.J. Lipps, D.A. Jans, Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Gen. 6, 299–310 (2005)
M.D. Brown, A.G. Schatzlein, I.F. Uchegbu, Gene delivery with synthetic (non-viral) carriers. Int. J. Pharmaceut. 229, 1–21 (2001)
D. Lechardeur, A. Verkman, G. Lukacs, Intracellular routing of plasmid DNA during non-viral gene transfer. Adv. Drug Deliv. Rev. 57, 755–767 (2005)
R. Kircheis, S. Schuller, S. Brunner et al., Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gen. Med. 1, 111–120 (1999)
T. Blessing, M. Kursa, R. Holzhauser et al., Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconj. Chem. 12, 529–537 (2001)
M.A. Wolfert, E.H. Schacht, V. Toncheva et al., Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers. Hum. Gen. Ther. 7, 2123–2133 (1996)
Y.H. Choi, F. Liu, J.S. Kim et al., Polyethylene glycol-grafted poly-l-lysine as polymeric gene carrier. J. Contr. Rel. 54, 39–48 (1998)
N. Shimizu, J. Chen, S. Gamou et al., Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. Can. Gen. Ther. 3, 113–120 (1996)
M. Hashida, S. Takemura, M. Nishikawa et al., Targeted delivery of plasmid DNA complexed with galactosylated poly(l-lysine). J. Contr. Rel. 53, 301–310 (1998)
J.M. Benns, J.S. Choi, R.I. Mahato et al., pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly (l-histidine)-graft-poly (l-lysine) comb shaped polymer. Bioconj. Chem. 11, 637–645 (2000)
J. Kim, A. Maruyama, T. Akaike et al., Terplex DNA delivery system as a gene carrier. Pharmaceut. Res. 15, 116–121 (1998)
S. Gao, J. Chen, L. Dong et al., Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur. J. Pharmaceut. Biopharmaceut. 60, 327–334 (2005)
M. Lavertu, S. Methot, N. Tran-Khanh et al., High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27, 4815–4824 (2006)
M. Huang, C.W. Fong, E. Khor et al., Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J. Contr. Rel. 106, 391–406 (2005)
H. Sang Yoo, J. Eun Lee, H. Chung et al., Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. J. Contr. Rel. 103, 235–243 (2005)
S. Mansouri, Y. Cuie, F. Winnik et al., Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 27, 2060–2065 (2006)
T. Kean, S. Roth, M. Thanou, Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J. Contr. Rel. 103, 643–653 (2005)
M. Koping-Hoggard, I. Tubulekas, H. Guan, et al., Chitosan as a nonviral gene delivery system. Structure–property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gen. Ther. 8, 1108–1121 (2001)
S.H. Pun, N.C. Bellocq, A. Liu et al., Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconj. Chem. 15, 831–840 (2004)
R.K. Tekade, T. Dutta, V. Gajbhiye et al., Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J. Microencap. 26, 287–296 (2009)
D. Luong, P. Kesharwani, R. Deshmukh et al., PEGylated PAMAM dendrimers: enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Act. Biomat. 43, 14–29 (2016)
N. Chaniotakis, K. Thermos, M. Kalomiraki, Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int. J. Nanomed. 11, 1–12 (2015)
Y. Cheng, Z. Xu, M. Ma et al., Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharmaceut. Sci. 97, 123–143 (2008)
D. Pandita, N. Poonia, S. Kumar et al., Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J. Pharm. Bioal. Sci. 6, 139 (2014)
Z. Zhou, X. Ma, C.J. Murphy et al., Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy. Ang. Chem. Int. Ed. 53, 10949–10955 (2014)
S. Hussain, Nanomedicine for treatment of lung cancer. Adv. Exp. Med. Biol. 890, 137–147 (2015)
C.M. Paleos, D. Tsiourvas, Z. Sideratou, Triphenylphosphonium decorated liposomes and dendritic polymers: prospective second-generation drug delivery systems for targeting mitochondria. Mol. Pharmaceut. 13, 2233–2241 (2016)
J.Y.C. Edgar, H. Wang, Introduction for design of nanoparticle based drug delivery systems. Curr. Pharmaceut. Des. 23, 2108–2112 (2017)
T.G. Mason, J.N. Wilking, K. Meleson et al., Nanoemulsions: formation, structure, and physical properties. Phys. Condens. Mat. 18, R635–R666 (2006)
H.J. Gi, S.N. Chen, J.S. Hwang et al., Studies of formation and interface of oil-water microemulsion. Chin. J. Phys. 30, 665–678 (1992)
H. Maeda, J. Wu, T. Sawa et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Contr. Rel. 65, 271–284 (2000)
G.P. Kumar, A. Divya, Nanoemulsion based targeting in cancer therapeutics. Med. Chem. 5, 272–284 (2015)
E. Sanchez-Lopez, M. Guerra, J. Dias-Ferreira et al., Current applications of nanoemulsions in cancer therapeutics. Nanomaterials 9, 821 (2019)
J.E. Kim, Y.J. Park, Improved antitumor efficacy of hyaluronic acid-complexed paclitaxel nanoemulsions in treating non-small cell lung cancer. Biomol. Ther. 25, 411–416 (2017)
C. Pucci, C. Martinelli, G. Ciofani, What does the future hold for chemotherapy with the use of lipid-based nanocarriers? Fut. Oncol. 16, 81–84 (2019)
A. Puri, K. Loomis, B. Smith et al., Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26, 523–580 (2009)
L. Bayon-Cordero, I. Alkorta, L. Arana, Application of solid lipid nanoparticles to improve the effciency of anticancer drugs. Nanomaterials 9, 474 (2019)
A. Ashtari, F. Niazvand, L. Khorsandi, Chemotherapy drugs based on solid lipid nanoparticles for breast cancer treatment. Medicina 56, 694 (2020)
Y. Zhuang, B. Xu, F. Huang et al., Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model. Pharmazie 67, 925–929 (2012)
N.K. Garg, B. Singh, A. Jain et al., Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics. Coll. Surf. B Bioint. 146, 114–126 (2016)
M.S. Oliveira, B. Aryasomayajula, B. Pattni et al., Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models. Int. J. Pharm. 512, 292–300 (2016)
M. Rizwanullah, J. Ahmad, S. Amin, Nanostructured lipid carriers: a novel platform for chemotherapeutics. Curr. Drug Deliv. 13, 4–26 (2016)
S. Selvamuthukumar, R. Velmurugan, Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lip. Heal Dis. 11, 159 (2012)
L. Zhang, Y. Li, J.C. Yu, Chemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatment. J. Mater. Chem. B 2, 452–470 (2014)
J. Conde, J.T. Dias, V. Graza et al., Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front. Chem. 2, 48 (2014)
E. Abbasi, T. Kafshdooz, M. Bakhtiary et al., Biomedical and biological applications of quantum dots. Artif. Cell Nanomed. Biotechnol. 44, 885–891 (2016)
K.S. Shabestari, M. Farshbaf, A. Akbarzadeh et al., Magnetic nanoparticles: preparation methods, applications in cancer diagnosis and cancer therapy. Artif. Cell Nanomed. Biotechnol. 45, 6–17 (2016)
D.A. Giljohann, D.S. Seferos, W.L. Daniel et al., Gold nanoparticles for biology and medicine. Ang. Chem. Int. Ed. 49, 3280–3294 (2010)
P.K. Jain, X. Huang, I.H. El-Sayed et al., Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc. Chem. Res. 41, 1578–1586 (2008)
N.S. Abadeer, C.J. Murphy, Recent progress in cancer thermal therapy using gold nanoparticles. J. Phys. Chem. C 120, 4691–4716 (2016)
H. Chugh, D. Sood, I. Chandra et al., Role of gold and silver nanoparticles in cancer nano-medicine. Artif. Cell Nanomed. Biotechnol. 46, 1210–1220 (2018)
R. Wang, H. Yang, R. Fu et al., Biomimetic upconversion nanoparticles and gold nanoparticles for novel simultaneous dual-modal imaging-guided photothermal therapy of cancer. Cancers 12(11), 3136 (2020)
H.J. Klasen, Historical review of the use of silver in the treatment of burns I. Early uses. Burns 26, 117–130 (2000)
Y. Li, Y. Chang, X. Lian, et al., Silver nanoparticles for enhanced cancer theranostics: in vitro and in vivo perspectives. J. Biomed. Nanotech. 14, 1515–1542 (2018)
D. Zhao, X. Sun, J. Tong et al., A novel multifunctional nanocomposite C225-conjugated Fe3O4/Ag enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy. Act. Biochim. Biophys. Sin. 44, 678–684 (2012)
M. Morais, A.L. Teixeira, F. Dias et al., Cytotoxic effect of silver nanoparticles synthesized by green methods in cancer. J. Med. Chem. 63, 14308–14335 (2020)
P. Wu, Y. Gao, Y. Lu et al., High specific detection and near-infrared photothermal therapy of lung cancer cells with high SERS active aptamer–silver–gold shell–core nanostructures. Analyst 138, 6501 (2013)
D. Guo, L. Zhu, Z. Huang et al., Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions. Biomaterials 34, 7884–7894 (2013)
S. Gurunathan, J.W. Han, V. Eppakayala et al., Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells. Biomed. Res. Int. 2013, 535796 (2013)
T. Vangijzegem, D. Stanicki, S. Laurent, Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Exp. Op. Drug. Deliv. 16, 69–78 (2018)
B. Chertok, B.A. Moffat, A.E. David et al., Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29, 487–496 (2008)
M.E. Kooi, V.C. Cappendijk, K.B.J.M. Cleutjens et al., Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circul 107, 2453–2458 (2003)
M. Arruebo, R. Fernandez-Pacheco, M.R. Ibarra et al., Magnetic nanoparticles for drug delivery. Nan. Today 2, 22–32 (2007)
A.S. Arbab, L.A. Bashaw, B.R. Miller et al., Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 229, 838–846 (2003)
C. Sun, J. Lee, M. Zhang, Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 60, 1252–1265 (2008)
C.J. Diederich, Thermal ablation and high-temperature thermal therapy: overview of technology and clinical implementation. Int. J. Hyperther. 21, 745–753 (2005)
L. Zhu, Z. Zhou, H. Mao, L. Yang, Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine 12, 73–87 (2017)
P. Juzenas, W. Chen, Y.P. Sun et al., Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv. Drug Deliv. Rev. 60, 1600–1614 (2008)
K.H. Chen, S. Wu, C.M. Cheng, Electrical properties of the thin films using a low temperature supercritical carbon dioxide fluid process. Int. J. Chem. Eng. App. 6, 455–459 (2015)
W. Yu, N. Yu, Z. Wang et al., Chitosan-mediated green synthesis and folic-acid modification of CuS quantum dots for photoacoustic imaging guided photothermal therapy of tumor. J. Coll. Interf. Sci. 555, 480–488 (2019)
W. Guo, Z. Qiu, C. Guo et al., Multifunctional theranostic agent of Cu2(OH)PO4 quantum dots for photoacoustic image-guided photothermal/photodynamic combination cancer therapy. ACS App. Mat. Interf. 9, 9348–9358 (2017)
B. Hosnedlova, M. Kepinska, S. Skalickova et al., Nano-selenium and its nanomedicine applications: a critical review. Int. J. Nanomed. 13, 2107–2128 (2018)
D.S. Karaman, M.P. Sarparanta, J.M. Rosenholm et al., Multimodality imaging of silica and silicon materials in vivo. Adv. Mat. 30, 1703651 (2018)
J. Saleem, L. Wang, C. Chen, Carbon-based nanomaterials for cancer therapy via targeting tumor microenvironment. Adv. Heal Mat. 7, e1800525 (2018)
A. Bianco, K. Kostarelos, M. Prato, Applications of carbon nanotubes in drug delivery. Curr. Op. Chem. Biol. 9, 674–679 (2005)
C.H. Wang, S.H. Chiou, C.P. Chou, et al., Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomed. Nanotech. Biol. Med. 7, 69–79 (2011)
T. Yang, Z. Wu, P. Wang et al., A large-inner-diameter multi-walled carbon nanotube-based dual-drug delivery system with pH-sensitive release properties. J. Mat. Sci. Mat. Med. 28, 110 (2017)
C. Spinato, A.P.R. de Garibay, M. Kierkowicz et al., Design of antibody-functionalized carbon nanotubes filled with radioactivable metals towards a targeted anticancer therapy. Nanoscale 8, 12626–12638 (2016)
J.T.-W. Wang, R. Klippstein, M. Martincic, et al., Neutron activated 153Sm sealed in carbon nanocapsules for in-vivo imaging and cancer radiotherapy. ACS Nano. 14, 129–141 (2020)
J.T.-W. Wang, C. Spinato, R. Klippstein, et al., Neutron irradiated antibody-functionalized carbon nanocapsules for target cancer radiotherapy. Carbon 162, 410–422 (2020)
M. Fiorillo, A.F. Verre, M. Iliut et al., Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy.” Oncotarget 6, 3553–3562 (2015)
Z. Wei, X. Yin, Y. Cai et al., Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma. Int. J. Nanomed. 13, 1505–1524 (2018)
D. De Melo-Diogo, R. Lima-Sousa, C.G. Alves et al., Graphene family nanomaterials for application in cancer combination photothermal therapy. Biomat. Sci. 7, 3534–3551 (2019)
M.J. Mitchell, R.K. Jain, R. Langer, Engineering and physical sciences in oncology: challenges and opportunities. Nat. Rev. Cancer 17, 659–675 (2017)
R.S. Riley, C.H. June, R. Langer et al., Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019)
P.N. Navya, A. Kaphle, S.P. Srinivas et al., Current trends and challenges in cancer management and therapy using designer nanomaterials. Nan. Conv. 6, 23 (2019)
V.K. Chaturvedi, A. Singh, V.K. Singh et al., Cancer nanotechnology: a new revolution for cancer diagnosis and therapy. Curr. Drug Met. 20, 416–429 (2019)
Y. Li, C. Ayala-Orozco, P.R. Rauta, et al., The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective. Nanoscale 11, 17157–17178 (2019)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ali, R., Ahmed, F., Chauhan, M. (2023). Theranostic Approaches for Diagnosis and Treatment of Cancer: An Update. In: Malviya, R., Sundram, S. (eds) Targeted Cancer Therapy in Biomedical Engineering. Biological and Medical Physics, Biomedical Engineering. Springer, Singapore. https://doi.org/10.1007/978-981-19-9786-0_18
Download citation
DOI: https://doi.org/10.1007/978-981-19-9786-0_18
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-9785-3
Online ISBN: 978-981-19-9786-0
eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)